← Leaderboards
Atique U. Ahmed
University Of Chicago
$7,632,613
Attributed
$7,632,613
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,632,613 · 6
By mechanism
R01$5,184,213 · 2
P50$1,633,836 · 2
R00$709,926 · 1
K99$104,638 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Chicago
Same institution · by research overlap
- Marc B Hershenson$21,013,981
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsTumorGlioblastomaBrainRecurrenceIn VivoPathway InteractionsTherapy ResistantMalignant NeoplasmsChemotherapyBloodResistancePreventRadiation TherapyMolecularMediatingTreatment EfficacyBaseCharacteristicsAnabolismEffective TherapyMalignant Neoplasm Of BrainCell DivisionGlioma
Grant awards (24)
Cellular Plasticity and equilibrium in GBM Progression$436,062
R01 · FY2025 · NS · contact PI
A Phase 1 Adaptive Dose Escalation Study of Mycophenolate Mofetil in Combination with Temozolomide for Patients with Newly Diagnosed Glioblastoma$311,764
P50 · FY2025 · CA · contact PI
Cellular Plasticity and equilibrium in GBM Progression$435,784
R01 · FY2024 · NS · contact PI
A Phase 1 Adaptive Dose Escalation Study of Mycophenolate Mofetil in Combination with Temozolomide for Patients with Newly Diagnosed Glioblastoma$301,266
P50 · FY2024 · CA · contact PI
Cellular Plasticity and equilibrium in GBM Progression$449,262
R01 · FY2023 · NS · contact PI
Role of purine metabolism in chemoresistance$345,625
R01 · FY2023 · NS · contact PI
A Phase 1 Adaptive Dose Escalation Study of Mycophenolate Mofetil in Combination with Temozolomide for Patients with Newly Diagnosed Glioblastoma$291,881
P50 · FY2023 · CA · contact PI
Cellular Plasticity and equilibrium in GBM Progression$442,662
R01 · FY2022 · NS · contact PI
Role of purine metabolism in chemoresistance$345,625
R01 · FY2022 · NS · contact PI
phase 1 adaptive dose-escalation study of mycophenolate mofetil (MMF) in combination with temozolomide (TMZ) for patients with newly diagnosed glioblastoma$289,507
P50 · FY2022 · CA · contact PI
phase 1 adaptive dose-escalation study of mycophenolate mofetil (MMF) in combination with temozolomide (TMZ) for patients with newly diagnosed glioblastoma$439,418
P50 · FY2021 · CA · contact PI
Role of purine metabolism in chemoresistance$345,625
R01 · FY2021 · NS · contact PI
Cellular plasticity and equilibrium in GBM progression$312,123
R01 · FY2021 · NS · contact PI
Role of purine metabolism in chemoresistance$345,625
R01 · FY2020 · NS · contact PI
Cellular plasticity and equilibrium in GBM progression$331,675
R01 · FY2020 · NS · contact PI
Role of purine metabolism in chemoresistance$345,625
R01 · FY2019 · NS · contact PI
Cellular plasticity and equilibrium in GBM progression$342,103
R01 · FY2019 · NS · contact PI
Cellular plasticity and equilibrium in GBM progression$346,300
R01 · FY2018 · NS · contact PI
Cellular plasticity and equilibrium in GBM progression$360,117
R01 · FY2017 · NS · contact PI
Genetically-Modified Neural Stem Cell Based Virotherapy for Invasive Gliomas$176,012
R00 · FY2015 · CA · contact PI
Genetically-Modified Neural Stem Cell Based Virotherapy for Invasive Gliomas$63,063
R00 · FY2015 · CA · contact PI
Genetically-Modified Neural Stem Cell Based Virotherapy for Invasive Gliomas$236,853
R00 · FY2014 · CA · contact PI
Genetically-Modified Neural Stem Cell Based Virotherapy for Invasive Gliomas$233,998
R00 · FY2013 · CA · contact PI
Genetically-Modified Neural Stem Cell Based Virotherapy for Invasive Gliomas$104,638
K99 · FY2012 · CA · contact PI